Novel combination therapy using IL-33 and Anti-Areg Antibodies Decreases Tumor Growth

University of Pittsburgh researchers have demonstrated through their studies that an anti-Areg antibody and IL-33 synergistically inhibited tumor growth. Pitt’s research establishes that Areg/EGFR is required for maintaining immune suppression during IL-33 immunotherapy IL-33, a human protein encoded in the IL33 gene, shows strong antitumor activities. IL-33 can also be combined with immune checkpoint inhibitors (ICIs) to further augment antitumor efficacy. Because IL-33 plays a multifaceted role in tumor immunity, its antitumor efficacy is limited, which makes it essential to define the underlying cellular networks of IL-33-driven tumoral immune responses.

Description

IL-33, a human protein encoded in the IL33 gene, shows strong antitumor activities. IL-33 can also be combined with immune checkpoint inhibitors (ICIs) to further augment antitumor efficacy. Because IL-33 plays a multifaceted role in tumor immunity, its antitumor efficacy is limited, which makes it essential to define the underlying cellular networks of IL-33-driven tumoral immune responses.

Applications

· Increase the response rate of immune checkpoint inhibitors for cancer patients.

Advantages

· Areg blockade and IL-33 combination therapy for cancer is novel therapy

Invention Readiness

In Vivo

IP Status

https://patents.google.com/patent/WO2023132926A2

Related Publication(s)

Sun, R., Zhao, H., Gao, D. S., Ni, A., Li, H., Chen, L., Lu, X., Chen, K., & Lu, B. (2023). Amphiregulin couples IL1RL1+ regulatory T cells and cancer-associated fibroblasts to impede antitumor immunity. Science Advances, 9(34). https://doi.org/10.1126/sciadv.add7399